| Ytd | -23.68% | |
| 1y | -68.70% |
| Open | 0.67 | Prev Close | 0.65 | Low | 0.67 | High | 0.67 | Mkt Cap | 4.23M |
| Vol | 350.00 | Avg Vol | 133.07K | EPS | -1.54 | P/E | -0.42 | Forward P/E | -3.08 |
| Beta | 1.50 | Short Ratio | 0.55 | Inst. Own | 43.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 0.80 | 200-d Avg | 0.93 | 1yr Est | 15.67 |
APRE News
Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stag
Presentation highlights early clinical activity from ACESOT-1051, including partial responses and st
Aprea Therapeutics (APRE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism ab
Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.22) per share which beat the analy
DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”,
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Ana
Pre-Market Stock Futures: Futures are trading modestly higher after a blowout midweek rally spurred
Oppenheimer analyst Matthew Biegler initiates coverage on Aprea Therapeutics (NASDAQ:APRE) with a
Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage
DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”
DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”
Wedbush analyst Robert Driscoll reiterates Aprea Therapeutics (NASDAQ:APRE) with a Outperform and
HC Wainwright & Co. analyst Joseph Pantginis maintains Aprea Therapeutics (NASDAQ:APRE) with
Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stag
Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Manag
Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined
Aprea Therapeutics (NASDAQ: APRE - Get Free Report) will likely be releasing its Q4 2025 results bef
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.32) per share which missed the ana
DOYLESTOWN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”
Aprea Therapeutics (NASDAQ: APRE) shares are trading higher on Wednesday as the company announced ad
Aprea Therapeutics shares rise after promising Phase 1 trial results with APR-1051 in cancer treatme
Tumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose level Pati
DOYLESTOWN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”
New patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea's WEE1 and A
Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 i
Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in end
DOYLESTOWN, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”,
APRE, NFE and CZR have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2026.
APRE, CULP and PSKY have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.
Aprea Therapeutics, Inc. (NASDAQ: APRE - Get Free Report) saw a significant decline in short interes
During Wednesday's trading, 517 companies set new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
On Friday, 431 companies hit new 52-week lows.